# Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study

> **NCT03254914** · — · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 3554 (actual)

## Conditions studied

- Hypertension

## Interventions

- **PROCEDURE:** Home Blood Pressure

## Key facts

- **NCT ID:** NCT03254914
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-09
- **Primary completion:** 2018-10-31
- **Final completion:** 2019-02-28
- **Target enrollment:** 3554 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254914, "Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03254914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*